NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors
Carl Maximilian Thielmann(German Cancer Research Center), Klaus Griewank(Düsseldorf University Hospital), Patrick Terheyden(University Hospital Schleswig-Holstein), Luisa Richter(German Cancer Research Center), Jochen Utikal(German Cancer Research Center), Edgar Dippel(Klinikum Ludwigshafen), Rudolf Herbst(Helios Klinikum Erfurt), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Inga Möller(Düsseldorf University Hospital), Michael Weichenthal(Christian-Albrechts-Universität zu Kiel), Claudia Pföhler(Saarland University), Dirk Schadendorf(National Center for Tumor Diseases), Friedegund Meier(National Center for Tumor Diseases), Peter Mohr(Elbe Kliniken Stade-Buxtehude), Georg Lodde(Essen University Hospital), Annette Paschen(University of Duisburg-Essen), Elisabeth Livingstone(German Cancer Research Center), Antje Sucker(German Cancer Research Center), Philipp Jansen(German Cancer Research Center), Rajmohan Murali(Memorial Sloan Kettering Cancer Center), Selma Ugurel(Klinikum Bielefeld), Lisa Zimmer(The University of Sydney), Anne Zaremba(National Center for Tumor Diseases), Johanna Matull(German Cancer Research Center), Eleftheria Chorti(German Cancer Research Center), Alexander Kreuter(HELIOS St. Elisabeth Klinik Oberhausen), Julia Kretz(German Cancer Research Center), Jens Ulrich, Eva Hadaschik(West German Heart and Vascular Center Essen)
Cited by 33
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k